During the past decade, Massachusetts General Hospital conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 19 clinical trials were completed, i.e. on average, 57.6% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 7 clinical trials were completed. i.e. 36.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Massachusetts General Hospital" #1 sponsor was "Massachusetts General Hospital" with 37 trials, followed by "National Cancer Institute (NCI)" with 9 trials sponsored, "Cyberonics, Inc." with 2 trials sponsored, "Knopp Biosciences" with 2 trials sponsored and "Amarin Neuroscience Ltd" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Massachusetts General Hospital" #1 collaborator was "National Institute of Mental Health (NIMH)" with 3 trials as a collaborator, "Beth Israel Deaconess Medical Center" with 2 trials as a collaborator, "European Commission" with 2 trials as a collaborator, "Huntington Study Group" with 2 trials as a collaborator and "Massachusetts General Hospital" with 2 trials as a collaborator. Other collaborators include 19 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Massachusetts General Hospital" are "Major Depressive Disorder" (6 trials), "Huntington's Disease" (5 trials), "Adult Glioblastoma" (4 trials), "Amyotrophic Lateral Sclerosis" (4 trials) and "Huntington Disease" (4 trials). Many other conditions were trialed in "Massachusetts General Hospital" in a lesser frequency.

Most popular intervention types in "Massachusetts General Hospital" are "Drug" (27 trials), "Other" (21 trials), "Device" (15 trials), "Behavioral" (8 trials) and "Biological" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Laboratory Biomarker Analysis" (5 trials), "Creatine monohydrate" (3 trials), "Bevacizumab" (2 trials) and "Cediranib Maleate" (2 trials). Other intervention names were less common.

The vast majority of trials in "Massachusetts General Hospital" are 66 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Massachusetts General Hospital". undefined are not yet recruiting, 19 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 42 completed trials in Massachusetts General Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Massachusetts General Hospital, 7 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 32 trials that are defined as “Not Applicable".